February 17, 2016 Off

Durvalumab granted BTD by FDA for cancer patients

By Dino Mustafić

AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.

January 20, 2016 Off

Ex-drug CEO Shkreli plans to replace lawyers

By Dino Mustafić

Former drug executive Martin Shkreli plans to hire new legal counsel to represent him against U.S. charges that he defrauded investors at his former hedge fund and a pharmaceutical company he headed, Shkreli’s current lawyers said.